Immune potentiators,termed adjuvants,trigger early innate immune responses to ensure the generation of robust and long-lasting adaptive immune responses of vaccines. Presented here is as tudy that takes advantage of as elfassembling small-molecule library for the development of an ovel vaccine adjuvant. Cell-based screening of the library and subsequent structural optimization led to the discovery of as imple,c hemically tractable deoxycholate derivative (molecule 6,a lso named cholicamide) whose well-defined nanoassembly potently elicits innate immune responses in macrophages and dendritic cells.F unctional and mechanistic analyses indicate that the virus-like assembly enters the cells and stimulates the innate immune response through Toll-like receptor 7(TLR7), an endosomal TLR that detects singlestranded viral RNA. As an influenza vaccine adjuvant in mice, molecule 6 was as potent as Alum, ac linically used adjuvant. The studies described here pave the way for anew approachto discovering and designing self-assembling small-molecule adjuvants against pathogens,i ncluding emerging viruses.

Immune potentiators, termed adjuvants, trigger early innate immune responses to ensure the generation of robust and long‐lasting adaptive immune responses of vaccines. Presented here is a study that takes advantage of a self‐assembling small‐molecule library for the development of a novel vaccine adjuvant. Cell‐based screening of the library and subsequent structural optimization led to the discovery of a simple, chemically tractable deoxycholate derivative (molecule 6, also named cholicamide) whose well‐defined nanoassembly potently elicits innate immune responses in macrophages and dendritic cells. Functional and mechanistic analyses indicate that the virus‐like assembly enters the cells and stimulates the innate immune response through Toll‐like receptor 7 (TLR7), an endosomal TLR that detects single‐stranded viral RNA. As an influenza vaccine adjuvant in mice, molecule 6 was as potent as Alum, a clinically used adjuvant. The studies described here pave the way for a new approach to discovering and designing self‐assembling small‐molecule adjuvants against pathogens, including emerging viruses.

The effective co-delivery of antigens and immune potentiators (adjuvants) and the high degree of antigen presentation have been two major challenges in the development of subunit vaccines. Here, we address...